Lv3
390 积分 2025-08-14 加入
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial
3天前
已完结
Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial
1个月前
已完结
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
1个月前
已完结
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
1个月前
已完结
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment
1个月前
已完结
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
1个月前
已完结
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement
1个月前
已完结
Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial
1个月前
已完结
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes
1个月前
已完结
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
1个月前
已完结
皖公网安备34019202002308
